{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:15:13Z","timestamp":1790262913652,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11596-023-2753-2","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:02:14Z","timestamp":1682748134000},"page":"539-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Yi-nuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"issue":"3","key":"2753_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2753_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med, 2017,14(1):9\u201332","journal-title":"Cancer Biol Med"},{"issue":"1","key":"2753_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","volume":"139","author":"JS Ferriss","year":"2015","unstructured":"Ferriss JS, Java JJ, Bookman MA, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology\/GOG study. Gynecol Oncol, 2015,139(1):17\u201322","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2753_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","volume":"32","author":"T Baert","year":"2021","unstructured":"Baert T, Ferrero A, Sehouli J, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol, 2021,32(6):710\u2013725","journal-title":"Ann Oncol"},{"issue":"49","key":"2753_CR5","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.18632\/oncotarget.27827","volume":"11","author":"JE den Ouden","year":"2020","unstructured":"den Ouden JE, Zaman GJR, Dylus J, et al. Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget, 2020,11(49):4570\u20134581","journal-title":"Oncotarget"},{"issue":"4","key":"2753_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer, 2013,13(4):273\u2013282","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2753_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/ijgc-2022-003353","volume":"32","author":"A Gallego","year":"2022","unstructured":"Gallego A, Mendiola M, Hernando B, et al. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. Int J Gynecol Cancer, 2022,32(8):1009\u20131016","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2753_CR8","doi-asserted-by":"publisher","first-page":"e0278849","DOI":"10.1371\/journal.pone.0278849","volume":"18","author":"A Jlassi","year":"2023","unstructured":"Jlassi A, Manai M, Morjen M, et al. VISTA+\/CD8+status correlates with favorable prognosis in Epithelial ovarian cancer. PLoS One, 2023,18(3):e0278849\u2013e","journal-title":"PLoS One"},{"issue":"12","key":"2753_CR9","doi-asserted-by":"publisher","first-page":"e157215","DOI":"10.1172\/jci.insight.157215","volume":"7","author":"M Ukita","year":"2022","unstructured":"Ukita M, Hamanishi J, Yoshitomi H, et al. CXCL13-producing CD4+T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight, 2022,7(12):e157215","journal-title":"JCI Insight"},{"issue":"12","key":"2753_CR10","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/cancers14122991","volume":"14","author":"E Amblard","year":"2022","unstructured":"Amblard E, Soumelis V. Context-Dependent Effects Explain Divergent Prognostic Roles of Tregs in Cancer. Cancers, 2022,14(12):2991","journal-title":"Cancers"},{"key":"2753_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-1-4939-8958-4_4","volume":"1904","author":"M Bhandaru","year":"2019","unstructured":"Bhandaru M, Rotte A. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. Methods Mol Biol, 2019,1904:83\u2013108","journal-title":"Methods Mol Biol"},{"issue":"5","key":"2753_CR12","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1182\/bloodadvances.2021005978","volume":"6","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, King AC, Geyer MB, et al. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. Blood Adv, 2022,6(5):1432\u20131443","journal-title":"Blood Adv"},{"issue":"6382","key":"2753_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science, 2018,359(6382):1350\u20131355","journal-title":"Science"},{"issue":"6230","key":"2753_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015,348(6230):62\u201368","journal-title":"Science"},{"issue":"9","key":"2753_CR15","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1002\/cam4.1700","volume":"7","author":"L Ni","year":"2018","unstructured":"Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med, 2018,7(9):4509\u20134516","journal-title":"Cancer Med"},{"issue":"12","key":"2753_CR16","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, et al. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci, 2021,22(12):6532","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2753_CR17","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1002\/jcp.28132","volume":"234","author":"SMY Mashhadi","year":"2019","unstructured":"Mashhadi SMY, Kazemimanesh M, Arashkia A, et al. Shedding light on the EpCAM: An overview. J Cell Physiol, 2019,234(8):12569\u201312580","journal-title":"J Cell Physiol"},{"issue":"1","key":"2753_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","volume":"38","author":"C Patriarca","year":"2012","unstructured":"Patriarca C, Macchi RM, Marschner AK, et al. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev, 2012,38(1):68\u201375","journal-title":"Cancer Treat Rev"},{"key":"2753_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.critrevonc.2018.03.006","volume":"126","author":"A Herreros-Pomares","year":"2018","unstructured":"Herreros-Pomares A, Aguilar-Gallardo C, Calabuig-Farinas S, et al. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. Crit Rev Oncol Hematol, 2018,126:52\u201363","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2753_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ijc.30099","volume":"139","author":"A Seeber","year":"2016","unstructured":"Seeber A, Untergasser G, Spizzo G, et al. Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer. Int J Cancer, 2016,139(3):657\u2013663","journal-title":"Int J Cancer"},{"issue":"5","key":"2753_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/bjc.2014.366","volume":"111","author":"P Massoner","year":"2014","unstructured":"Massoner P, Thomm T, Mack B, et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c\/205. Br J Cancer, 2014,111(5):955\u2013964","journal-title":"Br J Cancer"},{"issue":"2","key":"2753_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2006.03.035","volume":"103","author":"G Spizzo","year":"2006","unstructured":"Spizzo G, Went P, Dirnhofer S, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol, 2006,103(2): 483\u2013488","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2753_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/jcp.2007.049460","volume":"61","author":"A Brunner","year":"2008","unstructured":"Brunner A, Prelog M, Verdorfer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol, 2008,61(3):307\u2013310","journal-title":"J Clin Pathol"},{"issue":"5","key":"2753_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/his.12307","volume":"64","author":"D Fong","year":"2014","unstructured":"Fong D, Moser P, Kasal A, et al. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology, 2014,64(5):683\u2013692","journal-title":"Histopathology"},{"issue":"7","key":"2753_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.pathol.2018.08.013","volume":"50","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Chung KY, Kwon JE, et al. Expression of EpCAM in adenoid cystic carcinoma. Pathology, 2018,50(7):737\u2013741","journal-title":"Pathology"},{"issue":"3","key":"2753_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.31557\/APJCP.2023.24.3.929","volume":"24","author":"LO Gaghana","year":"2023","unstructured":"Gaghana LO, Miskad U, Cangara MH, et al. The Relationship Between Expression of EpCAM Cancer Stem Cell Marker with Histopathological Grading, Lymphovascular Invasion, and Metastases in Colorectal Adenocarcinoma. Asian Pac J Cancer Prev, 2023,24(3):929\u2013934","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2753_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/cas.12318","volume":"105","author":"Y Yang","year":"2014","unstructured":"Yang Y, Fei F, Song Y, et al. Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese. Cancer Sci, 2014,105(1):89\u201396","journal-title":"Cancer Sci"},{"key":"2753_CR28","doi-asserted-by":"publisher","first-page":"843604","DOI":"10.3389\/fcell.2022.843604","volume":"10","author":"Y Liao","year":"2022","unstructured":"Liao Y, Wu M, Jia Y, et al. EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients. Front Cell Dev Biol, 2022,10:843604","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2753_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/jcp.2011.090274","volume":"64","author":"G Spizzo","year":"2011","unstructured":"Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol, 2011, 64(5):415\u2013420","journal-title":"J Clin Pathol"},{"issue":"8","key":"2753_CR30","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3390\/ijms18081802","volume":"18","author":"CAM van der Fels","year":"2017","unstructured":"van der Fels CAM, Rosati S, de Jong IJ. EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study. Int J Mol Sci, 2017,18(8):1802","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2753_CR31","doi-asserted-by":"publisher","first-page":"eaav4275","DOI":"10.1126\/sciadv.aav4275","volume":"5","author":"X Liu","year":"2019","unstructured":"Liu X, Li J, Cadilha BL, et al. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv, 2019,5(6):eaav4275","journal-title":"Sci Adv"},{"issue":"5","key":"2753_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/IGC.0b013e3181a8331f","volume":"19","author":"S Bellone","year":"2009","unstructured":"Bellone S, Siegel ER, Cocco E, et al. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent\/Chemotherapy-Resistant Epithelial Ovarian Cancer Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. Int J Gynecol Cancer, 2009,19(5):860\u2013866","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2753_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1292\/jvms.20-0455","volume":"83","author":"J Fu","year":"2021","unstructured":"Fu J, Shang Y, Qian Z, et al. Chimeric antigen receptor-T (CAR-T) cells targeting epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model. J Vet Med Sci, 2021,83(2):241\u2013247","journal-title":"J Vet Med Sci"},{"issue":"7","key":"2753_CR34","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3390\/cancers12071762","volume":"12","author":"D van den Brand","year":"2020","unstructured":"van den Brand D, van Lith SAM, de Jong JM, et al. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. Cancers, 2020, 12(7):1762","journal-title":"Cancers"},{"key":"2753_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.actbio.2019.04.044","volume":"91","author":"S Lee","year":"2019","unstructured":"Lee S, Ahn HJ. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo. Acta Biomater, 2019,91:258\u2013269","journal-title":"Acta Biomater"},{"issue":"5","key":"2753_CR36","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.7150\/thno.17826","volume":"7","author":"J Zheng","year":"2017","unstructured":"Zheng J, Zhao S, Yu X, et al. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics, 2017,7(5):1373\u20131388","journal-title":"Theranostics"},{"key":"2753_CR37","doi-asserted-by":"publisher","first-page":"803059","DOI":"10.3389\/fphar.2022.803059","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Qiao Y, Zong H, et al. IgG-like Bispecific Antibody CD3xEpCAM Generated by Split Intein Against Colorectal Cancer. Front Pharmacol, 2022,13: 803059","journal-title":"Front Pharmacol"},{"issue":"3","key":"2753_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol, 2015,93(3):290\u2013296","journal-title":"Immunol Cell Biol"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.7150\/jca.2.309","volume":"2","author":"D Seimetz","year":"2011","unstructured":"Seimetz D. Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab (R)). J Cancer, 2011,2:309\u2013316","journal-title":"J Cancer"},{"issue":"10","key":"2753_CR40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2165\/11209040-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Catumaxomab in Malignant Ascites. Drugs, 2012,72(10): 1399\u20131410","journal-title":"Drugs"},{"issue":"9","key":"2753_CR41","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer, 2010,127(9): 2209\u20132221","journal-title":"Int J Cancer"},{"issue":"3","key":"2753_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cncr.29062","volume":"121","author":"DP English","year":"2015","unstructured":"English DP, Bellone S, Schwab CL, et al. Solitomab, an Epithelial Cell Adhesion Molecule\/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines In Vitro and Fresh Tumor Cells Ex Vivo. Cancer, 2015,121(3):403\u2013412","journal-title":"Cancer"},{"key":"2753_CR43","doi-asserted-by":"publisher","first-page":"105584","DOI":"10.1016\/j.ejps.2020.105584","volume":"158","author":"L Song","year":"2021","unstructured":"Song L, Xue J, Zhang J, et al. Mechanistic prediction of first-in-human dose for bispecific CD3\/EpCAM T-cell engager antibody M701, using an integrated PK\/PD modeling method. Eur J Pharm Sci, 2021,158:105584","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2753_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2217\/pme-2017-0071","volume":"15","author":"CM Zhang","year":"2018","unstructured":"Zhang CM, Yu LY, Lv JF, et al. Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell. Per Med, 2018,15(3):167\u2013179","journal-title":"Per Med"},{"issue":"1","key":"2753_CR45","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","volume":"5","author":"GH Giornelli","year":"2016","unstructured":"Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus, 2016,5(1):1197","journal-title":"Springerplus"},{"issue":"1","key":"2753_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13048-019-0588-z","volume":"12","author":"V Keyvani","year":"2019","unstructured":"Keyvani V, Farshchian M, Esmaeili SA, et al. Ovarian cancer stem cells and targeted therapy. J Ovarian Res, 2019,12(1):120","journal-title":"J Ovarian Res"},{"key":"2753_CR47","doi-asserted-by":"publisher","first-page":"604084","DOI":"10.3389\/fonc.2020.604084","volume":"10","author":"F Ning","year":"2021","unstructured":"Ning F, Cole CB, Annunziata CM. Driving Immune Responses in the Ovarian Tumor Microenvironment. Front Oncol, 2021,10:604084","journal-title":"Front Oncol"},{"issue":"2","key":"2753_CR48","first-page":"156","volume":"24","author":"B Melichar","year":"2001","unstructured":"Melichar B, Touskova M, Tosner J, et al. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie, 2001,24(2):156\u2013160","journal-title":"Onkologie"},{"issue":"2","key":"2753_CR49","doi-asserted-by":"publisher","first-page":"188436","DOI":"10.1016\/j.bbcan.2020.188436","volume":"1874","author":"F Fagotto","year":"2020","unstructured":"Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review. Biochim Biophys Acta Rev Cancer, 2020,1874(2):188436","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"2753_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","volume":"64","author":"J Landskron","year":"2015","unstructured":"Landskron J, Helland O, Torgersen KM, et al. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother, 2015,64(3):337\u2013347","journal-title":"Cancer Immunol Immunother"},{"issue":"51","key":"2753_CR51","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. PNAS, 2005,102(51):18538\u201318543","journal-title":"PNAS"},{"issue":"3","key":"2753_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 2003,348(3): 203\u2013213","journal-title":"N Engl J Med"},{"issue":"2","key":"2753_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","volume":"2","author":"R Linke","year":"2010","unstructured":"Linke R, Klein A, Seimetz D. Catumaxomab Clinical development and future directions. Mabs, 2010,2(2):129\u2013136","journal-title":"Mabs"},{"key":"2753_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.intimp.2017.10.008","volume":"54","author":"R Hong","year":"2018","unstructured":"Hong R, Zhou Y, Tian X, et al. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM\/CD3-bispecific BiTE antibody MT110 efficacy against IDO1(hi)breast cancer via enhancing immune cells activity. Int Immunopharmacol, 2018,54:118\u2013124","journal-title":"Int Immunopharmacol"},{"key":"2753_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-015-0241-7","volume":"34","author":"F Ferrari","year":"2015","unstructured":"Ferrari F, Bellone S, Black J, et al. Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE (R)), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res, 2015,34:123","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-023-2753-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2753-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T07:09:05Z","timestamp":1702451345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-023-2753-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1007\/s11596-023-2753-2","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}